FindTrial
Sign In

Phase I/II study of R340 (Capecitabine), L-OHP (Oxaliplatin) and R435 (Bevacizumab) in advanced and/or metastatic colorectal cancer

Phase I/II study of R340 (Capecitabine), L-OHP (Oxaliplatin) and R435 (Bevacizumab) in advanced and/or metastatic colorectal cancer

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220262
Enrollment
Unknown
Registered
2006-06-27
Start date
2006-06-27
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced and/or metastatic colorectal cancer

Interventions

investigational material(s) Generic name etc : Capecitabine|Oxaliplatin|Bevacizumab INN of investigational material : Therapeutic category code : 42- Antineoplastic agents Dosage and Administration f

Sponsors

Chugai Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: No previously treated for advanced or metastatic disease, PS 0-1

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Response Rate, Safety—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026